



## UNITED STATES ENVIRONMENTAL PROTECTION AGENCY

WASHINGTON, D.C. 20460

OFFICE OF  
PREVENTION, PESTICIDES  
AND TOXIC SUBSTANCES

Via Federal Express

T.R. Nelson, Ph.D.  
BASF Corporation  
26 Davis Dr.  
Research Triangle Park, NC 27709

Dear Dr. Nelson:

This letter is to transmit the Office of Pesticide Programs' (OPP) human health risk assessment and supporting documents as well as the ecological effects risk assessment for vinclozolin. An updated drinking water assessment will be sent separately within the next week. We are providing you with a 30-day period to comment on errors, confidential business information (CBI), and planned data. Your comments must be received within 30 days of receipt of this letter. The Agency will make corrections, if necessary, to the risk assessment documents and then place the risk assessments, your comments and the Agency's review and discussion of your comments into OPP's Public Docket. The docket will be opened for public comment for 60 days from the date of publication of a Notice of Data Availability in the *Federal Register*. Additionally, the risk assessments will be placed on the internet at the same time. This process is part of the Agency's efforts to involve the public in the implementation of the Food Quality Protection Act of 1996 and serves as an interim measure to improve the transparency of the reregistration and tolerance reassessment processes.

In the process of reviewing the Agency's risk assessments, we ask that you inform us in writing of any claims of CBI contained in the assessments. If we do not receive notification in writing of any such claims within 30 days, the Agency will assume that the documents are free of CBI. Also, we request that you inform the Agency of any pertinent, on-going or planned studies, or other sources of information on vinclozolin, and your timetable for completing and submitting such data and information to the Agency. This will enable the Agency to plan better for refining the risk assessments and completing the reregistration and tolerance reassessment.

Please mail your response, any claims of CBI and other information about vinclozolin to Deanna Scher, the Chemical Review Manager (CRM) for vinclozolin. In addition, provide the CRM with your response and any supporting material in both hard copy **and** electronic form. If you have any questions, please contact her at (703) 308-7043.

Sincerely,

Susan Lewis, Chief  
Reregistration Branch I  
Special Review and  
Reregistration Division